Literature DB >> 30963365

Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.

Waroonrat Sukarnjanaset1, Sutep Jaruratanasirikul2, Thitima Wattanavijitkul1.   

Abstract

This study aimed to characterize the population pharmacokinetics (PKs) of piperacillin and investigate probability of target attainment (PTA) and cumulative fraction of response (CFR) of various dosage regimens in critically ill patients during the early phase of sepsis. Forty-eight patients treated with piperacillin/tazobactam were recruited. Five blood samples were drawn before and during 0-0.5, 0.5-2, 2-4 and 4-6 or 8 h after administration. Population PKs was analyzed using NONMEM®. The PTA of 90%fT>MIC target and CFR were determined by Monte Carlo simulation. The two compartment model best described the data. Piperacillin clearance (CL) was 5.37 L/h, central volume of distribution (V1) was 9.35 L, and peripheral volume of distribution was 7.77 L. Creatinine clearance (CLCr) and mean arterial pressure had a significant effect on CL while adjusted body weight had a significant impact on V1. Subtherapeutic concentrations can occur during the early phase of sepsis in critically ill patients with normal renal function. The usual dosage regimen, 4 g of piperacillin infused over 0.5 h every 6 h, could not achieve the target for susceptible organisms with MIC 16 mg/L in patients with CLCr ≥ 60 mL/min. Our proposed regimen for the patients with CLCr 60-120 mL/min was an extended 2 h infusion of 4 g of piperacillin every 6 h. Most regimens provided CFR ≥ 90% for the E. coli infection while there was no dosage regimen achieved a CFR of 90% for the P. aeruginosa infection.

Entities:  

Keywords:  Critically ill patients; Pharmacodynamics; Piperacillin; Population pharmacokinetics; Sepsis; β-Lactams

Year:  2019        PMID: 30963365     DOI: 10.1007/s10928-019-09633-8

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  36 in total

Review 1.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

Authors:  George L Drusano
Journal:  Nat Rev Microbiol       Date:  2004-04       Impact factor: 60.633

2.  Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis.

Authors:  Danny Tsai; Penelope Stewart; Rajendra Goud; Stephen Gourley; Saliya Hewagama; Sushena Krishnaswamy; Steven C Wallis; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 3.  Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review.

Authors:  Abdulaziz S Alobaid; Maya Hites; Jeffrey Lipman; Fabio Silvio Taccone; Jason A Roberts
Journal:  Int J Antimicrob Agents       Date:  2016-02-23       Impact factor: 5.283

4.  Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?

Authors:  Maria Goul Andersen; Anders Thorsted; Merete Storgaard; Anders N Kristoffersson; Lena E Friberg; Kristina Öbrink-Hansen
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen.

Authors:  Roger Jelliffe
Journal:  Am J Nephrol       Date:  2002 Jul-Aug       Impact factor: 3.754

6.  Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?

Authors:  Jason A Roberts; Michael S Roberts; Thomas A Robertson; Andrew J Dalley; Jeffrey Lipman
Journal:  Crit Care Med       Date:  2009-03       Impact factor: 7.598

Review 7.  Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.

Authors:  Athena L V Hobbs; Katherine M Shea; Kirsten M Roberts; Mitchell J Daley
Journal:  Pharmacotherapy       Date:  2015-11       Impact factor: 4.705

8.  Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations.

Authors:  Carolin Fleischmann; André Scherag; Neill K J Adhikari; Christiane S Hartog; Thomas Tsaganos; Peter Schlattmann; Derek C Angus; Konrad Reinhart
Journal:  Am J Respir Crit Care Med       Date:  2016-02-01       Impact factor: 21.405

9.  Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?

Authors:  Kristina Öbrink-Hansen; Rasmus Vestergaard Juul; Merete Storgaard; Marianne Kragh Thomsen; Tore Forsingdal Hardlei; Birgitte Brock; Mads Kreilgaard; Jakob Gjedsted
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

10.  Continuous beta-lactam infusion in critically ill patients: the clinical evidence.

Authors:  Mohd H Abdul-Aziz; Joel M Dulhunty; Rinaldo Bellomo; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-08-16       Impact factor: 6.925

View more
  6 in total

Review 1.  Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.

Authors:  Ibrahim El-Haffaf; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-04-20       Impact factor: 6.447

2.  Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study.

Authors:  Vesa Cheng; Mohd H Abdul-Aziz; Fay Burrows; Hergen Buscher; Young-Jae Cho; Amanda Corley; Arne Diehl; Eileen Gilder; Stephan M Jakob; Hyung-Sook Kim; Bianca J Levkovich; Sung Yoon Lim; Shay McGuinness; Rachael Parke; Vincent Pellegrino; Yok-Ai Que; Claire Reynolds; Sam Rudham; Steven C Wallis; Susan A Welch; David Zacharias; John F Fraser; Kiran Shekar; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2021-08-30       Impact factor: 5.191

3.  Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools.

Authors:  Ferdinand Anton Weinelt; Miriam Songa Stegemann; Anja Theloe; Frieder Pfäfflin; Stephan Achterberg; Franz Weber; Lucas Dübel; Agata Mikolajewska; Alexander Uhrig; Peggy Kiessling; Wilhelm Huisinga; Robin Michelet; Stefanie Hennig; Charlotte Kloft
Journal:  Antibiotics (Basel)       Date:  2022-06-02

4.  Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation.

Authors:  Cristina Sanches; Geisa C S Alves; Andras Farkas; Samuel Dutra da Silva; Whocely Victor de Castro; Farah Maria Drummond Chequer; Francisco Beraldi-Magalhães; Igor Rafael Dos Santos Magalhães; André de Oliveira Baldoni; Mark D Chatfield; Jeffrey Lipman; Jason A Roberts; Suzanne L Parker
Journal:  Antibiotics (Basel)       Date:  2022-03-24

5.  Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation.

Authors:  Yong Kyun Kim; Hyoung Soo Kim; Sunghoon Park; Hwan-Il Kim; Sun Hee Lee; Dong-Hwan Lee
Journal:  J Antimicrob Chemother       Date:  2022-04-27       Impact factor: 5.758

6.  Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Simulation of Piperacillin/Tazobactam for Dosing Optimization in Late Elderly Patients with Pneumonia.

Authors:  Noriyuki Ishihara; Nobuhiro Nishimura; Kazuro Ikawa; Fumi Karino; Kiyotaka Miura; Hiroki Tamaki; Takahisa Yano; Takeshi Isobe; Norifumi Morikawa; Kohji Naora
Journal:  Antibiotics (Basel)       Date:  2020-03-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.